Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Anda Viksna"'
Autor:
Anda Viksna, Darja Sadovska, Vija Riekstina, Anda Nodieva, Ilva Pole, Renate Ranka, Iveta Ozere
Publikováno v:
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, Vol 37, Iss , Pp 100493- (2024)
Background: The recurrence of tuberculosis (TB) continues to place a significant burden on patients and TB programs worldwide. Repeated TB episodes can develop either due to endogenous reactivation of previously treated TB or exogenous reinfection wi
Externí odkaz:
https://doaj.org/article/25472fa876b646a382bb7341729b2eb3
Autor:
Viktorija Ulanova, Agnija Kivrane, Anda Viksna, Leonora Pahirko, Lauma Freimane, Darja Sadovska, Iveta Ozere, Andra Cirule, Eduards Sevostjanovs, Solveiga Grinberga, Dace Bandere, Renate Ranka
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Objectives: Isoniazid is a key drug in the chemotherapy of tuberculosis (TB), however, interindividual variability in pharmacokinetic parameters and drug plasma levels may affect drug responses including drug induced hepatotoxicity. The current study
Externí odkaz:
https://doaj.org/article/c4c2861429c14d29a0cb8b08315e9f4c
Autor:
Agnija Kivrane, Viktorija Ulanova, Solveiga Grinberga, Eduards Sevostjanovs, Anda Viksna, Iveta Ozere, Ineta Bogdanova, Maksims Zolovs, Renate Ranka
Publikováno v:
Pharmaceutics, Vol 16, Iss 3, p 388 (2024)
Genetic polymorphisms can exert a considerable impact on drug pharmacokinetics (PK) and the development of adverse drug reactions (ADR). However, the effect of genetic polymorphisms on the anti-tuberculosis (anti-TB) drug, and particularly rifampicin
Externí odkaz:
https://doaj.org/article/2e9f5fa4aeb749c399c85653c3f349ee
Publikováno v:
Pharmacogenomics and Personalized Medicine. 15:959-965
Viktorija Igumnova,1,2 Agnija Kivrane,1,2 Anda Viksna,3,4 Inga Norvaisa,4 Renate Ranka1,2 1Molecular Microbiology Group, Latvian Biomedical Research and Study Centre, Riga, Latvia; 2Department of Pharmaceutical Chemistry, Riga Stradins University, Ri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed3010318340e1832bfaf014fdb360d1
https://doi.org/10.2147/pgpm.s371709
https://doi.org/10.2147/pgpm.s371709
Autor:
Ilva Pole, Anda Viksna, Viktorija Igumnova, Agnija Kivrane, Janis Kimsis, Lauma Freimane, Renate Ranka, Darja Sadovska
Publikováno v:
Pharmacogenomics. 22:519-527
Aim: To evaluate the application of next-generation sequencing-based targeted protocol for full-length CYP3A4 gene sequencing analysis. Materials & methods: The developed sequencing protocol was applied to analyze human DNA samples (n = 7) obtained f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd661c8329c7869937cb8081650674fd
https://doi.org/10.2217/pgs-2020-0128
https://doi.org/10.2217/pgs-2020-0128
Autor:
Solveiga Grinberga, Viktorija Igumnova, Osvalds Pugovics, Renate Ranka, Andra Cirule, Ilva Pole, Anda Viksna, Alvils Krams, Dace Bandere, Agnija Kivrane, Eduards Sevostjanovs
The pharmacokinetic profiling of drug substances and corresponding metabolites in the biological matrix is one of the most informative tools for the treatment efficacy assessment. Therefore, to satisfy the need for comprehensive monitoring of anti-tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6169ccd3de15caf305253636e059f775
https://zenodo.org/record/5716255
https://zenodo.org/record/5716255
Autor:
Agnija, Kivrane, Viktorija, Igumnova, Janis, Kimsis, Lauma, Freimane, Darja, Sadovska, Anda, Viksna, Ilva, Pole, Renate, Ranka
Publikováno v:
Pharmacogenomics. 22(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::28382e2ddd342aa4dd3d417d4fc144da
https://pubmed.ncbi.nlm.nih.gov/34003019
https://pubmed.ncbi.nlm.nih.gov/34003019
Autor:
Darja Sadovska, Iveta Ozere, Ilva Pole, Jānis Ķimsis, Annija Vaivode, Anda Vīksna, Inga Norvaiša, Ineta Bogdanova, Viktorija Ulanova, Valentīna Čapligina, Dace Bandere, Renāte Ranka
Publikováno v:
Frontiers in Public Health, Vol 12 (2024)
BackgroundTuberculosis remains a global health threat, and the World Health Organization reports a limited reduction in disease incidence rates, including both new and relapse cases. Therefore, studies targeting tuberculosis transmission chains and r
Externí odkaz:
https://doaj.org/article/b7b34d8295d64f59816d7d108ec2635c
Autor:
Anda Vīksna, Darja Sadovska, Iveta Berge, Ineta Bogdanova, Annija Vaivode, Lauma Freimane, Inga Norvaiša, Iveta Ozere, Renāte Ranka
Publikováno v:
BMC Infectious Diseases, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Multidrug-resistant tuberculosis (MDR–TB) remains a major public health problem in many high tuberculosis (TB) burden countries. Phenotypic drug susceptibility testing (DST) take several weeks or months to result, but line probe
Externí odkaz:
https://doaj.org/article/a2d4c6d16b3d4762a63fc692e83605dc